-
Boehringer Ingelheim Pharmaceuticals Inc. et al v. Aurobindo Pharma Ltd. et al DC
- 1:18-cv-01757
- D. Del.
- Judge: Colm F. Connolly
+1
- Filed: 11/07/2018
- Closed: 12/12/2022
- Latest Docket Entry: 12/12/2022
- PACER
- Docket updated daily
3
Plaintiffs
2
Defendants
12
Accused
Products
3
Patents-in-Suit
1,497
Days in
Litigation
-
Boehringer Ingelheim Pharmaceuticals Inc. et al v. Aurobindo Pharma Ltd. et al DC
- 1:18-cv-01757
- D. Del.
- Judge: Colm F. Connolly
+1
- Filed: 11/07/2018
- Closed: 12/12/2022
- Latest Docket Entry: 12/12/2022
- PACER
- Docket updated daily
Cause of Action
Infringement
Assigned Judge
Outcome Summary
- Patent Information
-
Infringement
Aurobindo Pharma Limited
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 10 mg/5 mg empagliflozin/linagliptin tablets10 mg empagliflozin tablets12.5 mg/1 g empagliflozin and metformin hydrochloride extended release tablets12.5 mg/1 g empagliflozin and metformin hydrochloride tablets12.5 mg/500 mg empagliflozin and metformin hydrochloride extended release tablets12.5 mg/500 mg empagliflozin and metformin hydrochloride tablets25 mg/5 mg empagliflozin/linagliptin tablets25 mg empagliflozin tablets5 mg/1 g empagliflozin and metformin hydrochloride extended release tablets5 mg/1 g empagliflozin and metformin hydrochloride tablets5 mg/500 mg empagliflozin and metformin hydrochloride extended release tablets5 mg/500 mg empagliflozin and metformin hydrochloride tablets | US 8,551,957 B2 | All Asserted Claims |
Infringement
Entry 13
|
| 10 mg/5 mg empagliflozin/linagliptin tablets10 mg empagliflozin tablets12.5 mg/1 g empagliflozin and metformin hydrochloride extended release tablets12.5 mg/1 g empagliflozin and metformin hydrochloride tablets12.5 mg/500 mg empagliflozin and metformin hydrochloride extended release tablets12.5 mg/500 mg empagliflozin and metformin hydrochloride tablets25 mg/5 mg empagliflozin/linagliptin tablets25 mg empagliflozin tablets5 mg/1 g empagliflozin and metformin hydrochloride extended release tablets5 mg/1 g empagliflozin and metformin hydrochloride tablets5 mg/500 mg empagliflozin and metformin hydrochloride extended release tablets5 mg/500 mg empagliflozin and metformin hydrochloride tablets | US 9,949,998 B2 | All Asserted Claims |
Infringement
Entry 13
|
Aurobindo Pharma USA Incorporated
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 10 mg/5 mg empagliflozin/linagliptin tablets10 mg empagliflozin tablets12.5 mg/1 g empagliflozin and metformin hydrochloride extended release tablets12.5 mg/1 g empagliflozin and metformin hydrochloride tablets12.5 mg/500 mg empagliflozin and metformin hydrochloride extended release tablets12.5 mg/500 mg empagliflozin and metformin hydrochloride tablets25 mg/5 mg empagliflozin/linagliptin tablets25 mg empagliflozin tablets5 mg/1 g empagliflozin and metformin hydrochloride extended release tablets5 mg/1 g empagliflozin and metformin hydrochloride tablets5 mg/500 mg empagliflozin and metformin hydrochloride extended release tablets5 mg/500 mg empagliflozin and metformin hydrochloride tablets | US 8,551,957 B2 | All Asserted Claims |
Infringement
Entry 13
|
| 10 mg/5 mg empagliflozin/linagliptin tablets10 mg empagliflozin tablets12.5 mg/1 g empagliflozin and metformin hydrochloride extended release tablets12.5 mg/1 g empagliflozin and metformin hydrochloride tablets12.5 mg/500 mg empagliflozin and metformin hydrochloride extended release tablets12.5 mg/500 mg empagliflozin and metformin hydrochloride tablets25 mg/5 mg empagliflozin/linagliptin tablets25 mg empagliflozin tablets5 mg/1 g empagliflozin and metformin hydrochloride extended release tablets5 mg/1 g empagliflozin and metformin hydrochloride tablets5 mg/500 mg empagliflozin and metformin hydrochloride extended release tablets5 mg/500 mg empagliflozin and metformin hydrochloride tablets | US 9,949,998 B2 | All Asserted Claims |
Infringement
Entry 13
|
